Live Breaking News & Updates on Oregon Medical Research Center|Page 4

Stay updated with breaking news from Oregon medical research center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Strategy Shows Promise for Psoriasis Remission in Early Study

The study is investigating whether high-dose IL-23 inhibition can target resident memory T cells and thereby induce long-term remission. ....

United States , Christopher Ritchlin , Andrew Blauvelt , Oregon Medical Research Center , National Psoriasis Foundation , University Of Rochesterny Medical Center , American Academy Of Dermatology , Drug Administration , Diseases Program Of The Accelerating Medicine Partnership , National Psoriasis , Psoriasis Area , Severity Index , American Academy , Medical Center , Immune Mediated Diseases Program , Accelerating Medicine Partnership , Psoriatic Arthritis , Biologic Therapy , Oint Inflammation , Interleukin 2 , Sol 2 , Autoimmune Disease , Chronic Disease , Chronic Illness , Clinical Research , Clinical Trials ,

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation –
SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ . ....

United States , Northwestern University , New York , San Francisco , Nordrhein Westfalen , Thomas Bieber , Jonathan Zalevsky , David Rosmarin , Andrew Blauvelt , Mary Tagliaferri , Zachary Lee , Brian Kotzin , Eli Lilly , Vivian Wu , Sohail Chaudhry , Sstephen Schleicher , Danni Yu , Mario Marcondes , Raj Chovatiya , David Rosen , Alisa Beck , Timothy Rodgers , Jonathan Silverberg , Yi Liu , Carsten Schmitz , Melinda Gooderham ,

Dr Andy Blauvelt: Drug Approval, Accessibility Challenges in Treating Patients with AD

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD). ....

United States , Sandy Blauvelt , Oregon Medical Research Center , Oregon Medical Research ,

Dupilumab Outcomes Stable in Open-Label AD Study

Other recent research on the biologic has shown that it improves lesional skin barrier function and rapidly reduces the abundance of Staphylococcus aureus on lesional skin. ....

United States , Sanofi Genzyme , Alisa Beck , Andrew Blauvelt , National Institute Of Allergy , University Of Rochester , University Of Rochester Medical Center , Oregon Medical Research Center , Atopic Dermatitis Research Network , Revolutionizing Atopic Dermatitis , Rochester Medical Center , National Institute , Infectious Diseases , Eczema Area , Severity Index , Peak Pruritus Numerical Rating Scale , Atopic Dermatitis , Biologic Therapy , Clinical Research , Clinical Trials , Linical Studies , Topical Corticosteroids , Corneal Disease , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech ,

Patients see atopic dermatitis improvement with switch from dupilumab to upadacitinib

Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment, according to a study.“Dupilumab was the first biologic approved to treat [atopic dermatitis (AD)]; however, after 16 weeks of treatment, fewer than 40% of patients achieve clear or almost clear skin and ....

United States , Andrew Blauvelt , Oregon Medical Research Center , Worst Pruritus Numerical Rating Scale ,